Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258193 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00258193 is a Phase 2 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT00258193, a Phase 2 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
* The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS. * The secondary objectives of this trial are: 1. To compare the dose ranging pharmacodynamic effects of placebo, and 100 and 1000 ug MD-1100 Acetate once daily on time to first bowel movement after first drug intake. 2. To describe and summarize the effects of placebo, and 100 and 1000 ug MD-1100 Acetate once daily on stool frequency, stool consistency, ease of passage and sensation of incomplete evacuation during the Treatment Period relative to Baseline.
Interventions
- DRUG MD-1100 Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258193
The ClinicalTrials.gov registry entry for NCT00258193 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MD-1100 Acetate is the first listed.
NCT00258193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00258193 about?
NCT00258193 is a clinical study titled "Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS". * The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in patients with C-IBS. * The secondary objectives of this trial are: 1. To compare the dose ranging p...
What is the current status of trial NCT00258193?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2006-01. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00258193?
The interventions under investigation include: MD-1100 Acetate (DRUG).
Who is sponsoring clinical trial NCT00258193?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.